Sex Differences in the Recognition, Monitoring, and Management of CKD in Health Care: An Observational Cohort Study
Top Cited Papers
- 1 October 2022
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 33 (10) , 1903-1914
Abstract
Introduction: Reported sex differences in the etiology, population prevalence, progression rates, and health outcomes of people with CKD may be explained by differences in health care. Methods: We evaluated sex as the variable of interest in a health care–based study of adults (n=227,847) with at least one outpatient eGFR2 measurement denoting probable CKD in Stockholm from 2009 to 2017. We calculated the odds ratios for diagnosis of CKD and provision of RASi and statins at inclusion, and hazard ratios for CKD diagnosis, visiting a nephrologist, or monitoring creatinine and albuminuria during follow-up. Results: We identified 227,847 subjects, of whom 126,289 were women (55%). At inclusion, women had lower odds of having received a diagnostic code for CKD and were less likely to have received RASi and statins, despite having guideline-recommended indications. In time-to-event analyses, women were less likely to have received a CKD diagnosis (HR, 0.43; 95% CI, 0.42 to 0.45) and visited a nephrologist (HR, 0.46; 95% CI, 0.43 to 0.48) regardless of disease severity, presence of albuminuria, or criteria for referral. Women were also less likely to undergo monitoring of creatinine or albuminuria, including those with diabetes or hypertension. These differences remained after adjustment for comorbidities, albuminuria, and highest educational achievement, and among subjects with confirmed CKD at retesting. Although in absolute terms all nephrology-care indicators gradually improved over time, the observed sex gap persisted. Conclusions: There were profound sex differences in the detection, recognition, monitoring, referrals, and management of CKD. The disparity was also observed in people at high risk and among those who had guideline-recommended indications. Podcast: This article contains a podcast at https://www.asn-online.org/media/podcast/JASN/2022_10_11_JASN2022030373.mp3.Keywords
Funding Information
- Vetenskapsrådet (2019-01059)
This publication has 47 references indexed in Scilit:
- The revised Lund-Malmö GFR estimating equation outperforms MDRD and CKD-EPI across GFR, age and BMI intervals in a large Swedish populationClinical Chemistry and Laboratory Medicine (CCLM), 2014
- Lifetime Incidence of CKD Stages 3-5 in the United StatesAmerican Journal of Kidney Diseases, 2013
- Lifetime Risk of ESRDJournal of the American Society of Nephrology, 2012
- Patients Who Plan for Conservative Care Rather Than Dialysis: A National Observational Study in AustraliaAmerican Journal of Kidney Diseases, 2012
- Study of Heart and Renal Protection (SHARP): Randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney diseaseAmerican Heart Journal, 2010
- Telmisartan, Ramipril, or Both in Patients at High Risk for Vascular EventsNew England Journal of Medicine, 2008
- Longitudinal Study of Racial and Ethnic Differences in Developing End-Stage Renal Disease among Aged Medicare BeneficiariesJournal of the American Society of Nephrology, 2007
- Low Rates of Testing and Diagnostic Codes Usage in a Commercial Clinical LaboratoryJournal of the American Society of Nephrology, 2005
- Angiotensin-Converting Enzyme Inhibitors and Progression of Nondiabetic Renal DiseaseAnnals of Internal Medicine, 2001
- The Effect of Angiotensin-Converting-Enzyme Inhibition on Diabetic NephropathyNew England Journal of Medicine, 1993